Alector, Inc. ALEC
Alector, Inc. (Nasdaq: ALEC) is a CNS/neurology/psychiatry drug developer. Its lead program, AL137, is in Phase 1 for Alzheimer's disease. Its next catalyst on record is AL137: First-in-human subcutaneous dosing in Australia (April 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: AL137 — First-in-human subcutaneous dosing in Australia (April 2027). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| latozinemab (AL001) | Frontotemporal dementia due to GRN mutation (FTD-GRN) | antibody | Phase 3 |
| nivisnebart (AL101/GSK4527226) | Alzheimer's disease | antibody | Phase 2 |
| AL137 | Alzheimer's disease (amyloid beta targeting) | antibody | Phase 1 |
| AL164 | Alzheimer's disease and other tauopathies (tau siRNA) | RNA (siRNA) | Pre-clinical |
| AL062 | Parkinson's disease and Lewy body dementia (alpha-synuclein siRNA) | RNA (siRNA) | Pre-clinical |
| ADP065-ABC | Multiple neurodegenerative conditions (NLRP3 siRNA) | RNA (siRNA) | Pre-clinical |
| AL050 | Parkinson's disease (GCase deficiency) | protein/peptide | Pre-clinical |
| AL037 | Alzheimer's disease (amyloid beta targeting, backup to AL137) | antibody | Pre-clinical |
Recent results and decisions
- Oct 21, 2025missed INFRONT-3 Phase 3 missed the clinical co-primary endpoint (CDR plus NACC FTLD-SB); plasma progranulin co-primary was significant but no effect on secondary/exploratory biomarkers or vMRI; OLE and continuation study discontinued.
did not meet the clinical co-primary endpoint of slowing FTD-GRN progression
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.